Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue 4, 2005, Pages 209-216

  Ebrahimi, Ramin ^a,e   Lincoff, A Michael ^b   Bittl, John A ^c   Chew, Derek ^d   Wolski, Kathy ^a   Wadhan, Nitin ^a   Toggart, Edward J ^a   Topol, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Munroe Regional Med Center   (United States)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Bivalirudin; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; CREATINE KINASE; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

ADULT; ALGORITHM; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 29344433826     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840501000401     Document Type: Review

References (31)

1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 301:61-68, 1979
2. Denardo SJ, Davis KE, Tcheng JE. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 149:138-144, 2005
3. Braunwald E, Antman EM, Beasley JW, et al. for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106:1893-1900, 2002
4. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142:929-931, 2001
5. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 143:847-853, 2002
6. Lincoff AM, Bittl JA, Kleiman NS, et al; REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93:1092-1096, 2004
7. Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863, 2003
8. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 44:1792-1800, 2004
9. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 106:V275-284, 2002
10. Popma JJ, Prpic R, Lansky AJ, Piana R. Heparin dosing in patients undergoing coronary intervention. Am J Cardiol 82:19P-24P, 1998
11. Harrington RA. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Semin Thromb Hemost 30:639-647, 2004
12. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:648-948, 2001
13. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 81:36-40, 1998
14. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997
15. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 69:157-163, 1993
16. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin. Am J Cardiol 82:12P-18P, 1998
17. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622-1629, 1993
18. Weitz JI, Bates SM. Acute coronary syndromes: A focus on thrombin. J Invasive Cardiol 14(suppl B):2B-7B, 2002
19. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 12(suppl F):41F-52F, 2000
20. Lincoff AM, Kleiman NS, Kereiakes DJ, et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292:696-703, 2004
21. Gurm HS, Rajagopal V, Fathi R, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol 95:716-721, 2005
22. Kugelmass AD, Cohen DJ, Houser F, et al. The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: A report from the HCA database. J Invasive Cardiol 15:568-574, 2003
23. Laskey WK, Selzer F, Vlachos HA, et al; Dynamic Registry Investigators. Comparison of in-hospital and 1-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 90:1062-1067, 2002
24. Tsang J, Sheppard R, Mak KH, et al; ROSETTA Investigators. Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: Results from the ROSETTA registry. Am Heart J 143:124-129, 2002
25. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113-1119, 2002
26. Konstance R, Tcheng JE, Wightman MB, et al. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. J Interv Cardiol 17:65-70, 2004
27. Mukherjee D, Wainess RM, Dimick JB, et al. Variation in outcomes after percutaneous coronary intervention in the United States and predictors of periprocedural mortality. Cardiology 103:143-147, 2005
28. Cohen HA, Williams DO, Holmes DR Jr, et al; NHLBI Dynamic Registry. Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: A report from the NHLBI Dynamic Registry. Am Heart J 146:513-519, 2003
29. Marso SP, Giorgi LV, Johnson WL, et al. Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: An analysis of 25,223 patients over 20 years. Am Heart J 145:270-277, 2003
30. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146, 1999
31. Chew DP, Lincoff AM, Gurm H, et al; REPLACE-2 Investigators. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a sub-analysis of the REPLACE-2 trial). Am J Cardiol 95:581-585, 2005